Zobrazeno 1 - 10
of 13
pro vyhledávání: ''
Autor:
Hirofumi Ikuta, Rei Onishi, Akinori Minato, Katsuyoshi Higashijima, Ikko Tomisaki, Naohiro Fujimoto
Publikováno v:
Cancer investigation. 37(10)
The oncological benefit of pelvic lymph node dissection (PLND) is still debatable because data on clinical outcomes of radical prostatectomy (RP) without PLND are lacking. In this study, we reported oncological outcome in consecutive 146 patients who
Autor:
Lucia Di Brina, Stefano Tomatis, Pierina Navarria, Ciro Franzese, Arturo Chiti, Marta Scorsetti, Egesta Lopci, Giuseppe D'Agostino, Pietro Mancosu
Publikováno v:
Cancer investigation. 35(9)
aim is outcome of 11C-Choline-PET guided SBRT on lymph node metastases.patients with 1 - 4 lymph node metastases detected by 11C-choline-PET were treated with SBRT. Toxicity, treated metastases control and Progression Free Survival were computed.twen
Publikováno v:
Cancer Investigation. 31:177-182
Introduction: This study evaluated objective response and safety for the combination of granulocyte macrophage-colony stimulating factor (GM-CSF), ketoconazole, and mitoxantrone in castration-resistant prostate cancer (CRPC) patients who previously f
Improvement of Prostate Cancer Detection by Integrating the PSA Test With miRNA Expression Profiling
Autor:
Thijs Wu, Xiaowu Pang, Yubin Hao, Xinbin Gu, Yuan Zhao, Joseph A. Califano, Chunnian He, Xiaoyun Zhao
Publikováno v:
Cancer Investigation. 29:318-324
Prostate-specific antigen (PSA) test is limited in prostate cancer diagnosis due to its inaccuracy. A new approach which integrates the PSA test with miRNA profiling was investigated to improve prostate cancer diagnosis. Six prostate cancer-related m
Publikováno v:
Cancer Investigation. 27:984-988
Purpose: To evaluate the incidence of skeletal complications in patients with multiple myeloma, and metastatic breast, prostate, or lung cancers, when therapy with intravenous bisphosphonates is continued for longer than 21 months. Methods: The prima
Publikováno v:
Cancer Investigation. 20:157-165
Little is known about etiologic factors for prostate cancer. Several studies have suggested a protective effect of diabetes mellitus on the risk of prostate cancer, though a study by our group has found an elevated risk of prostate cancer following i
Publikováno v:
Cancer investigation. 32(7)
Pyruvate kinase M2 (PKM2) is essential for aerobic glycolysis, the dominant metabolic pathway utilized by cancer cells. To determine the association of PKM2 with prostate cancer (PC), we examined 29 primary PC and three lymph node metastatic tumors;
Publikováno v:
Cancer investigation. 20(5-6)
Estramustine 600 mg/m2 can be administered safely with 225 mg/m2 of paclitaxel if administered as a 3-hr infusion for the treatment of hormone refractory prostate cancer. Significant anti-tumor activity has been reconfirmed despite the change in sche
Autor:
Sabah Sallah, Gregory A. Gagnon
Publikováno v:
Cancer investigation. 18(3)
Tumor-associated proteases play a major role in determining the biologic behavior and aggressiveness of prostate cancer. Several authors have described the association between the increased levels of urokinase plasminogen activator in the plasma and
Autor:
Charlesworth E. Rae, Willie Kreis, Martin Feuerman, M. Blumenfrucht, Basil S. Kasimis, J. Cogswell, George Wilding, Shirley S. Hwang, Harriet Steafather, Victor T. Chang
Publikováno v:
Cancer investigation. 18(7)
Patients with hormone-naive stage D2 prostate cancer often benefit from castration. This treatment, however, frequently produces many unacceptable physical and psychological side effects, especially in younger and sexually active patients. Bicalutami